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neuronal activity in the locus creruleus5-7 and decreased
noradrenaline release.8.9 While clonidine and the opiates have
similar effects on the locus coeruleus, clonidine appears to exert
specific effects through non-opiate, alpha-2 adrenergic recep-
tors. 6, These data suggested that the opiate-withdrawal syn-
drome is due to increased noradrenergic neuronal activity in
areas such as the locus coeruleus which are regulated both by
alpha-2 adrenergic and opiate receptors.
Our preliminary results in man support a noradrenergic sys-
tem mediation of opiate withdrawal and suggest that clonidine
may be a more definitive treatment for opiate withdrawal than
others now available.
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HLA AND CONGENITAL ADRENAL HYPERPLASIA
LINKAGE CONFIRMED
SiR,--Congenital adrenal hyperplasia (c.A.H.) is an auto-
somal recessive disease, associated in most cases with 21-hyd-
roxylase deficiency. 1,2 Dupont et al. suggested that the locus
responsible for 21-hydroxylase deficiency is in close linkage
with the HLA system. We have typed six families with one or
more children with C.A.H. and report data supporting this link-
age (table).
HLA typing was done by the standard two-stage National
Institutes of Health lymphocytotoxicity test. 118 different sera
were used to detect HLA A, B, and C antigens with the excep-
tion of CW6. In all families in which the segregation of W4
and W6 could be determined these antigens behaved as
expected. In all families the segregation of the HLA haplotypes
was established. Seven children with C.A.H. confirmed biochemi-
cally to be due to 21-hydroxylase deficiency were studied. The
salt-losing form of 21-hydroxylase deficiency was present in
four families while the remaining families (A and E) had the
non-salt-losing form.
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In family B both children had the HLA haplotype A3,
BW47. The children seemed to be HLA homozygous although
the parents were not first cousins and denied any known con-
sanguinity. Family A was ascertained through child 5, a girl
with C.A.H. The HLA typing of the family showed that her
oldest brother was HLA identical. This 23-year-old man was
further investigated and on both clinical and biochemical
grounds was considered to be homozygous for 21-hydroxylase
deficiency. Thus, the diagnosis was first suggested by HLA typ-
ing and then confirmed by clinical and biochemical studies
(this case will be discussed in greater detail elsewhere). In a
Pakistani family (F) the parents were first cousins and the only
affected child was an HLA homozygote. In this family, child
4 carried a maternal HLA A/C,B recombinant haplotype while
inheriting the same paternal haplotype as the affected sib.
Thus, the two children (4 and 5) are HLA indentical at the A
locus but different at the C, B loci showing that the gene for
C.A.H. segregated with HLA-B rather than with HLA-A since
child 4 "escaped" 21-hydroxylase deficiency. In three families
(C, D, and E) with two children discordant for 21-hydroxylase
deficiency the affected and unaffected children were not HLA
identical.
In our families and those of Dupont et al. no recombination
between the HLA-B locus and the gene for C.A.H. has been
found in a total of 35 children (or a total of 40 meiotic div-
isions including the family F first cousins). However, two
recombinants between HLA A and B have been found in the
twelve families. No association between particular HLA
antigens and 21-hydroxylase deficiency gene occurred.
These findings have implications for both prenatal and post-
natal diagnosis of 21-hydroxylase deficiency. Biochemical tests,
though encouraging, have not yet provided unequivocal means
of diagnosis in fetal life.’ If diagnosis proves possible by the
HLA typing of amniotic cells taken in the second trimester, it
will allow parents with a previous previously affected child the
opportunity to consider selective abortion. The ethics of abor-
tion of a fetus with a condition amenable to postnatal treat-
ment and compatible with life must be carefully considered.
Unequivocal diagnosis in early pregnancy would make the
more positive goal of prenatal treatment to prevent clitoral en-
largement more feasible. HLA types of amniotic cells in late
pregnancy or of cord-blood lymphocytes would supplement
biochemical studies and allow early diagnosis and prompt
treatment. Finally, identification of heterozygotes can be made
with greater certainty thus facilitating the study of the carrier
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HLA GENOTYPES IN SIX FAMILIES WITH C.A.H.
* Affected child. t 2 1-hydroxylase deficiency homozygote, clinically normal (see text).
t HLA recombinant: HLA-AI,-B5/Al, Bw35,Cw4.
F = father; M = mother.
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state and distinguishing the mildly affected homozygote in dif-
ficult cases. 5
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SIR,-We can confirm that the gene for adrenogenital syn-
drome (21-hydroxylase deficiency type) is closely linked to
HLA, as reported by Dupont et a1.1 1
Three kindreds (A, B, and C) were ascertained through a
female child with raised urinary 17-ketosteroids and virilising
adrenogenital syndrome. Two of the propositi have affected
brothers (raised urinary 17-ketosteroids); all five children have
responded to corticosteroids. Genetic marker data on the indi-
viduals in family A have been reported previously as part of
a study of a kindred with a chromosome abnormality.2 The ab-
normality has lately been determined to be a translocation
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t(2;10) (q21;q24)3 and is believed to be unrelated to adreno-
genital syndrome. This family was HLA typed several years
ago, with a limited range of HLA antisera. The results of typ-
ing the three kindreds for the closely linked chromosome 6
markers,4 HLA-A, HLA-B, Bf (properdin factor B), and red
cell glyoxalase are shown in table i.
A summary of lod scoress (logarithm of the odds) for linkage
of the HLA-B, Bf region with adrenogenital syndrome is
shown in table n. Dupont et al.’ used e, corrections in the cal-
culation of the scores in their families. We believe this is not
appropriate in the calculation of lod scores for linkage of a
recessive trait with a co-dominant, multiallelic marker such as
HLA. Lod scores for the families of Dupont et al. have been
recalculated directly from first principles, without corrections,
and are presented in table i. The recalculated peak lod score
is 4.6 instead of 3.4. Since HLA-B and Bf are very closely
linked,4 we have used information from both systems to deter-
mine the parental contribution of genes in this region of chro-
mosome 6 in the three new families. Thus, the assignment of
3. Weitkamp, L. R., Ferguson-Smith, M. A., Guttormsen, S. A., Huntzinger,
R. S., Chaganti, R. S. K., German, J., Schanfield, M. S. ibid. (in the
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5. Morton, N. E. Am. J. hum. Genet. 1955, 7, 277
TABLE I-CHROMOSOME 6 HAPLOTYPES IN THREE FAMILIES WITH ADRENOGENITAL SYNDROME
TABLE II-LOD SCORES FOR LINKAGE BETWEEN HLA-B (OR Bf) AND ADRENOGENITAL SYNDROME (21-HYDROXYLASE DEFICIENCY A.G.S.)
*Families 1-6 of Dupont et at.
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adrenogenital syndrome to the HLA region is confirmed with
a total peak lod score > 6 (odds of 106 :1) at -L 2 - 000.
Two additional conclusions may be drawn from these data.
First there is no evidence that the genes for the salt-losing and
compensated forms of adrenogenital syndrome have a different
linkage distance to HLA-B. Second, Dupont et al. observed
that adrenogenital syndrome is on the HLA-B side of HLA-A,
basing the suggestion on a single family with an HLA-B:
HLA-A recombinant. Child 2 in our family A is either a pater-
nal Bf:HLA-A recombinant or a maternal HLA-B:HLA-A
recombinant. In the former case the adrenogenital syndrome
gene segregates with Bf, and in the latter the gene segregates
with HLA-B, confirming, in either event, that the gene for the
adrenogenital syndrome is on the HLA-B side of HLA-A.
There is no evidence for association of the gene(s) for
adrenogenital syndrome with a specific HLA-B allele in the
nine reported families; thus, the HLA-B and adrenogenital-
syndrome loci are apparently far enough apart for linkage dis-
equilibrium not to be prominent. The adrenogenital syndrome
locus (loci) may lie as much as a few centimorgans from
HLA-B. More precise mapping will be possible when red-cell-
glyoxalase : HLA recombinants are found in families with the
adrenogenital syndrome.
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PRENATAL DIAGNOSIS OF PRIMARY PITUITARY
DYSGENESIS
SiR,-Primary pituitary dysgenesis is a rare inherited dis-
ease in which where we may find hypoglycxmia, respiratory
distress, small sella turcica, hypothyroidism, adrenal insuffi-
ciency, and ectopic testes.1,2
We have attempted prenatal diagnosis in two pregnancies at
risk for primary pituitary dysgenesis. These were the 5th and
6th pregnancies. The results of the lst and the 4th were nor-
mal girls. The other two gave affected boys.l.2 The parents are
cousins.
Prolactin activity was measured in amniotic fluid obtained
at 16 weeks’ gestation. Amniotic fluid was frozen until ana-
lysed. Prolactin activity was measured in 20 amniotic fluids
from controls at the same gestational age. Prolactin was mea-
sured by double-antibody radioimmunoassay.3 Prolactin levels
were low (355 ng/ml) in the 5th pregnancy. The parents
wanted to continue the pregnancy; the result was an affected
boy. In the 6th pregnancy prolactin levels were normal (1500
ng/ml).
Clements et al.1 found that prolactin levels in amniotic fluid
averaged 1314 ng/ml (range 270-2950) at 15-17 weeks. None
of our controls had a prolactin level at 16 weeks fetal age un-
der 1337 ng/ml (range 1337-2487).
The 6th pregnancy was continued and a normal girl was
born. She is now 6 months old, and hormone studies, X-rays
of the sella turcica, and bone age are normal. Serum-prolactin
was measured at 2 days of age and found to be 202 ng/ml
(term cord-blood values averaged 199 ng/ml).
Prenatal diagnosis of primary pituitary dysgenesis early
1. Willard, D., and others. Nouv. Presse m&eacute;d. 1972, 1, 2237.
2. Willard, D., Messer, J., Freysz, H. Archs fi Pediat. 1974, 31, 347.
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Metab. 1977, 44, 408.
enough to give the parents of an affected fetus the choice of
termination of pregnancy now seems possible.
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CIMETIDINE MAINTENANCE: HOW LONG?
Sm,&mdash;Dr Blackwood and colleagues (March 25, p. 626)
found that nearly all duodenal ulcers which- had been healed
by an initial course of cimetidine relapsed if not further treated
(21 out of 24 placebo-treated patients had recurrent duodenal
ulcers within six months of initial healing) while only 5 out of
21 patients had ulcer recurrences during a six-month period of
treatment with bedtime cimetidine. Blackwood et al. conclude
that bedtime cimetidine prevents relapse of duodenal ulcers.
Almost identical suppression of the tendency of duodenal
ulcers to relapse has been noted with two different cimetidine
maintenance regimens studied in unpublished trials done in
Nottingham (and Lincoln) and Dundee. In Nottingham twice
daily cimetidine (400 mg morning and night) resulted in a
relapse-rate of only 25% after six months; 75% of ulcers which
had healed after an initial course of cimetidine, relapsed within
six months during treatment with placebo. In Dundee 98 pa-
tients were maintained in full doses of cimetidine (200 mg
three times daily after food and 400 mg at night) for three to
twelve months after primary healing of the duodenal ulcers.
The recurrence-rate was 19%. Thus cimetidine not only heals
most duodenal ulcers but also it usually prevents relapse of
healed ulcers when treatment with the drug is continued for
six to twelve months.
Unfortunately Blackwood et al. do not say what happened
to their patients after maintenance treatment with cimetidine
was stopped. In Nottingham a further 40% of the cimetidine-
treated patients relapsed during eight months after cessation of
maintenance treatment, raising the rate of recurrence to about
70%. In Dundee follow-up for nearly two years after the end
of maintenance treatment revealed relapse in a further 44%,
giving a rate of relapse during and after treatment of 63%. It
is not clear whether these overall relapse-rates differ signifi-
cantly from the rate of relapse of placebo-treated patients, so
we still do not know how long we need to treat patients with
cimetidine before we can be sure that we are not merely defer-
ring their visit to the surgeon.
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HBs Ag IN SUPERFICIAL ARTERY OF PATIENT
WITH POLYMYALGIA RHEUMATICA
SIR,-Liver enzyme and other functional abnormalities in
polymyalgia rheumatica are well known. Corticosteroid ther-
apy rapidly reverses these anomalies.1.2 Liver biopsy usually
reveals normal parenchyma or fatty degeneration,I,3 but in one
case granulomatous hepatitis associated with fatty degenera-
tion and thickening of the walls of small intrahepatic arteries
has been reported .4
Hepatitis B antigen (HBsAg) has never been found in cases
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